Improving Vision and Quality of Life in Patients With Glaucoma Using Non-invasive Brain Stimulation and Perceptual Learning: A Randomized Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Glaucoma is a complex disease that can result in progressive vision loss. It is the second leading cause of blindness, accounting for 23% of permanent blindness in Hong Kong. There are no treatments that restore vision lost to glaucoma. However, recent studies have shown that vision can be improved by perceptual learning (PL) and transcranial electrical stimulation (tES). This study will examine the effect of perceptual learning and tES on improving quality of life, visual function and functional performance in patients with peripheral field loss due to glaucoma. It is phase 2 of Glaucoma Rehabilitation Using ElectricAI Transcranial Stimulation (GREAT) project.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age range from 18 to 80 years;

• Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes;

• A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of -6dB) within the central 24 degree of the visual field for at least one eye;

• Best-corrected distance visual acuity of 6/12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved).

• Stable vision and visual field loss for at least 3 months;

• With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function).

Locations
Other Locations
Hong Kong Special Administrative Region
The Hong Kong Polytechnic University
RECRUITING
Hong Kong
Contact Information
Primary
Allen Cheong, PhD
allen.my.cheong@polyu.edu.hk
852-27666108
Backup
Melinna Mei, PhD
melinna.mei@polyu.edu.hk
852-34002309
Time Frame
Start Date: 2023-05-15
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 144
Treatments
Experimental: Real-PL + Real-tES (tDCS)
Participant will receive 30 training sessions with real PL and real tES (tDCS): 3-4 sessions per week, about 1 hour per session
Experimental: Real-PL + Sham-tES (tDCS)
Participant will receive 30 training sessions with real PL and sham tES (tDCS): 3-4 sessions per week, about 1 hour per session
Placebo_comparator: Placebo-PL + Sham-tES (tDCS)
Participant will receive 30 training sessions with placebo PL and sham tES (tDCS): 3-4 sessions per week , about 1 hour per session
Related Therapeutic Areas
Sponsors
Collaborators: The University of Hong Kong, University of Waterloo, University of Magdeburg
Leads: The Hong Kong Polytechnic University

This content was sourced from clinicaltrials.gov